Top

Published in:

01-06-2008 | lab. investigation-human/animal tissue

XRCC1 and XRCC3 variants and risk of glioma and meningioma

Authors: Anne Kiuru, Carita Lindholm, Sirpa Heinävaara, Taina Ilus, Päivi Jokinen, Hannu Haapasalo, Tiina Salminen, Helle Collatz Christensen, Maria Feychting, Christoffer Johansen, Stefan Lönn, Beatrice Malmer, Minouk J. Schoemaker, Anthony J. Swerdlow, Anssi Auvinen

Published in: Journal of Neuro-Oncology | Issue 2/2008

Abstract

Several single nucleotide polymorphisms (SNPs) affecting DNA repair capacity and modifying cancer susceptibility have been described. We evaluated the association of SNPs Arg194Trp, Arg280His, and Arg399Gln in the X-ray cross-complementing group 1 (XRCC1) and Thr241Met in the X-ray cross-complementing group 3 (XRCC3) DNA repair genes with the risk of brain tumors. The Caucasian study population consisted of 701 glioma (including 320 glioblastoma) cases, 524 meningioma cases, and 1,560 controls in a prospective population-based case–control study conducted in Denmark, Finland, Sweden, and the UK. The studied SNPs were not significantly associated with the risk of brain tumors. The highest odds ratios (ORs) for the associations were observed between the homozygous variant genotype XRCC1 Gln399Gln and the risk of glioma (OR = 1.32; 95% confidence interval, CI, 0.97–1.81), glioblastoma (OR = 1.48; 95% CI, 0.98–2.24), and meningioma (OR = 1.34; 95% CI, 0.96–1.86). However, in pair-wise comparisons a few SNP combinations were associated with the risk of brain tumors: Among others, carriers of both homozygous variant genotypes, i.e., XRCC1 Gln399Gln and XRCC3 Met241Met, were associated with a three-fold increased risk of glioma (OR = 3.18; 95% CI, 1.26–8.04) and meningioma (OR = 2.99; 95% CI, 1.16–7.72). In conclusion, no significant association with brain tumors was found for any of the polymorphisms, when examined one by one. Our results indicated possible associations between combinations of XRCC1 and XRCC3 SNPs and the risk of brain tumors.

Ron E, Modan B, Boice JD Jr et al (1988) Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med 319:1033–1039PubMedCrossRef

Sadetzki S, Chetrit A, Freedman L et al (2005) Long-term follow-up for brain tumour development after childhood exposure to ionising radiation for tinea capitis. Radiat Res 163:424–432PubMedCrossRef

Goode EL, Ulrich CM, Potter JD (2002) Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 11:1513–1530PubMed

Hung RJ, Hall J, Brennan P et al (2005) Genetic polymorphisms in the base excision repair pathways and cancer risk: a HuGE review. Am J Epidemiology 162:925–942CrossRef

Audebert M, Salles B, Calsou P (2004) Involvement of poly(ADP-ribose)polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem 279:55117–55126PubMedCrossRef

Shen MR, Jones IM, Mohrenweiser H (1998) Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 58:604–608PubMed

Thompson LH, Schild D (2002) Recombinational DNA repair and human disease. Mutat Res 509:49–78PubMed

Khanna KK, Jackson SP (2001) DNA double-strand breaks: signaling, repair, and the cancer connection. Nat Genet 27:247–254PubMedCrossRef

Bishop DK, Ear U, Bhattacharyya A et al (1998) XRCC3 is required for assembly of Rad51 complexes in vivo. J Biol Chem 273:21482–21488PubMedCrossRef

10.

Pierce AJ, Johnson RD, Thompson LH et al (1999) XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 23:2633–2638CrossRef

11.

Caldecott K, Jeggo P (1991) Cross-sensitivity of gamma-ray-sensitive hamster mutants to cross-linking agents. Mutat Res 255:111–121PubMed

12.

Wang L-E, Bondy ML, Shen H et al (2004) Polymorphisms of DNA repair genes and risk of glioma. Cancer Res 64:5560–5563PubMedCrossRef

13.

Felini MJ, Olshan AF, Schroeder JC et al (2007) DNA repair polymorphisms XRCC1 and MGMT and risk of adult gliomas. Neuroepidemiology 29:55–58PubMedCrossRef

14.

Sadetzki S, Flint-Richter P, Starinsky S et al (2005) Genotyping of patients with sporadic and radiation-associated meningiomas. Cancer Epidemiol Biomarkers Prev 14:969–976PubMedCrossRef

15.

Cardis E, Richardson L, Deltour I et al (2007) The INTERPHONE study: design, epidemiological methods, and description of the study population. Eur J Epidemiol 22:647–664PubMedCrossRef

16.

Au WW, Navasumrit P, Ruchirawat M (2004) Use of biomarkers to characterize functions of polymorphic DNA repair genotypes. Int J Hyg Environ Health 207:301–313PubMedCrossRef

17.

Kiuru A, Lindholm C, Heilimo I et al (2005) Influence of DNA repair gene polymorphisms on the yield of chromosomal aberrations. Environ Mol Mutagen 46:198–205PubMedCrossRef

18.

Schaid DJ, Rowland CM, Tines DE et al (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70:425–434PubMedCrossRef

19.

Matullo G, Guarrera S, Carturan S et al (2001) DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case–control study. Int J Cancer 92:562–567PubMedCrossRef

20.

Smith TR, Miller MS, Lohman K et al (2003) Polymorphisms of XRCC1 and XRCC3 genes and susceptibility to breast cancer. Cancer Lett 190:183–190PubMedCrossRef

21.

Wacholder S, Chanock S, Garcia-Closas M et al (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96:434–442PubMedCrossRef

22.

Hattersley AT, McCarthy MI (2005) What makes a good genetic association study? Lancet 366:1315–1323PubMedCrossRef

23.

Wacholder S, Rothman N, Caporaso N (2000) Population stratification in epidemiologic studies of common variants and cancer: quantification of bias. J Natl Cancer Inst 92:1151–1158PubMedCrossRef

24.

Wrensch M, Wiencke JK, Wiemels J et al (2006) Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res 66:4531–4541PubMedCrossRef

25.

Lahkola A, Auvinen A, Raitanen J et al (2007) Mobile phone use and risk of glioma in 5 North European countries. Int J Cancer 120:1769–1775PubMedCrossRef

Title: XRCC1 and XRCC3 variants and risk of glioma and meningioma
Authors: Anne Kiuru
Carita Lindholm
Sirpa Heinävaara
Taina Ilus
Päivi Jokinen
Hannu Haapasalo
Tiina Salminen
Helle Collatz Christensen
Maria Feychting
Christoffer Johansen
Stefan Lönn
Beatrice Malmer
Minouk J. Schoemaker
Anthony J. Swerdlow
Anssi Auvinen
Publication date: 01-06-2008
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2008
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-008-9556-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

XRCC1 and XRCC3 variants and risk of glioma and meningioma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2008

Expression of vascular endothelial growth factor-A and mRNA stability factor HuR in human meningiomas

Pituitary gland involvement by a gamma delta hepatosplenic lymphoma, a mimicker of pituitary adenoma: report of a rare case

Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status

Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas

Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation

Glioblastoma multiforme with an abscess: case report and literature review